Zoledronic Acid Injection, Solution
Product Images NDC 63323-966

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 63323-966). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zoledronic04 (Zoledronic04)

Label for Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL) sterile solution for intravenous infusion by Fresenius Kabi USA, LLC. The label includes dosage form, strength, storage instructions, infusion time advisory, a pharmacist note, and barcode with NDC 63323-966-00. It is a 100 mL single dose vial.*

FDA Label Image

Zoledronic05 (Zoledronic05)

Packaging label for Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL) intravenous solution. The label shows the brand and generic name, strength, dosage form, and indicates it is a single-dose clear glass vial. It includes storage instructions, pharmacist dispensing information, and manufacturer Fresenius Kabi USA, LLC details with a barcode and NDC 63323-966-00.*

FDA Label Image

Zoledronic01 (Zoledronic01)

Chemical structure diagram of Zoledronic Acid, showing its molecular components including two phosphonic acid groups attached to a heterocyclic nitrogen-containing ring. The structure includes water and hydroxyl groups as part of the molecule representation.*

FDA Label Image

Zoledronic02 (Zoledronic02)

A Kaplan-Meier survival curve graph showing time to first hip fracture (months) comparing Zoledronic Acid injection, solution (5 mg/100mL) with placebo. The x-axis represents time in months, and the y-axis shows the cumulative incidence. The graph includes a stratified log-rank test p-value of 0.0024, indicating statistical comparison between the two groups.*

FDA Label Image

Zoledronic03 (Zoledronic03)

Two bar graphs comparing Zoledronic Acid and Risedronate over time. The first graph shows Therapeutic Response Rate (%) at days 10, 29, 63, 91, and 182. The second graph shows Serum Alkaline Phosphatase (SAP) Normalization (%) at days 1, 28, 63, 91, and 182. Zoledronic Acid demonstrates higher response and SAP normalization rates compared to Risedronate at most time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.